A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

NCT00502294 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Intravenous Steroid-Refractory Ulcerative Colitis

Interventions

DRUG: Visilizumab (HuM291; Nuvion®)

Sponsor

Facet Biotech

Collaborators

[object Object]